Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Loyse

Showing results (11-20 of 58) with videos related to

Pageof 6
Sort By:
AIDS (London, England)|May 20, 2009
High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll outJoseph N Jarvis, Andrew Boulle, Angela Loyse, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 14, 2017
Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature ReviewEstelle Pasquier, John Kunda, Pierre De Beaudrap, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2008
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trialTihana Bicanic, Robin Wood, Graeme Meintjes, et al.
The Lancet. Infectious Diseases|June 6, 2013
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countriesAngela Loyse, Harry Thangaraj, Philippa Easterbrook, et al.
Nature Reviews. Neurology|November 26, 2016
Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapyPeter R Williamson, Joseph N Jarvis, Anil A Panackal, et al.
Antimicrobial Agents and Chemotherapy|July 12, 2017
Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant TuberculosisAmber Arnold, Graham S Cooke, Onn Min Kon, et al.
The Journal of Infection|September 25, 2019
A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UKKavina Manalan, Nathan Green, Amber Arnold, et al.
The Journal of Infection|December 22, 2016
Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008-2014Amber Arnold, Graham S Cooke, Onn Min Kon, et al.
The Lancet. Infectious Diseases|September 1, 2022
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysisRadha Rajasingham, Nelesh P Govender, Alexander Jordan, et al.
Frontiers in Microbiology|March 30, 2018
Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS TestElvis Temfack, Charles Kouanfack, Leonella Mossiang, et al.
Pageof 6

Showing results (11-20 of 58) with videos related to

Sort By:
Pageof 6
AIDS (London, England)|May 20, 2009
High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll outJoseph N Jarvis, Andrew Boulle, Angela Loyse, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 14, 2017
Long-term Mortality and Disability in Cryptococcal Meningitis: A Systematic Literature ReviewEstelle Pasquier, John Kunda, Pierre De Beaudrap, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 29, 2008
High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trialTihana Bicanic, Robin Wood, Graeme Meintjes, et al.
The Lancet. Infectious Diseases|June 6, 2013
Cryptococcal meningitis: improving access to essential antifungal medicines in resource-poor countriesAngela Loyse, Harry Thangaraj, Philippa Easterbrook, et al.
Nature Reviews. Neurology|November 26, 2016
Cryptococcal meningitis: epidemiology, immunology, diagnosis and therapyPeter R Williamson, Joseph N Jarvis, Anil A Panackal, et al.
Antimicrobial Agents and Chemotherapy|July 12, 2017
Adverse Effects and Choice between the Injectable Agents Amikacin and Capreomycin in Multidrug-Resistant TuberculosisAmber Arnold, Graham S Cooke, Onn Min Kon, et al.
The Journal of Infection|September 25, 2019
A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UKKavina Manalan, Nathan Green, Amber Arnold, et al.
The Journal of Infection|December 22, 2016
Drug resistant TB: UK multicentre study (DRUMS): Treatment, management and outcomes in London and West Midlands 2008-2014Amber Arnold, Graham S Cooke, Onn Min Kon, et al.
The Lancet. Infectious Diseases|September 1, 2022
The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysisRadha Rajasingham, Nelesh P Govender, Alexander Jordan, et al.
Frontiers in Microbiology|March 30, 2018
Cryptococcal Antigen Screening in Asymptomatic HIV-Infected Antiretroviral Naïve Patients in Cameroon and Evaluation of the New Semi-Quantitative Biosynex CryptoPS TestElvis Temfack, Charles Kouanfack, Leonella Mossiang, et al.
Pageof 6